KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and safety of hetrombopag, a novel thrombopoietin receptor agonist, in children and adolescents with immune thrombocytopenia: results from a randomized, multicenter, placebo-controlled phase 3 trial.

Runhui Wu, Ju Gao, Yufeng Liu, Jie Yu, Shaoyan Hu, Hui Liang, Hui Jiang, Xiaowen Zhai, Min Zhou, Wenge Hao, Heng Mei, Fei Li, Yumei Chen, Wei Liu, Mei Yan, Runzi Li, Junye Xiong, Zhenyi Zhu, Xiaoling Cheng, Tianyou Wang

J Hematol Oncol 19(1) 24

PMID41952212
PMCIDPMC13067530
DOI10.1186/s13045-026-01790-x
发表日期2026-04-09
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:图注未提示 KM 曲线;Fig. 2:图注未提示 KM 曲线;Fig. 3:图注未提示 KM 曲线。
摘要

摘要

BACKGROUND: Primary immune thrombocytopenia (ITP) is the most common acquired bleeding disorder in children, and management is challenging when first-line therapy fails. Hetrombopag is an oral thrombopoietin receptor agonist (TPO-RA). This phase 3 randomized, double-blind, placebo-controlled trial evaluated its efficacy and safety in children and adolescents with ITP who had an inadequate response or relapse after prior treatment. METHODS: Children and adolescents aged 6-17 years were randomized 2:1 to receive once-daily hetrombopag (initial dose 2.5 mg) or placebo for 12 weeks, followed by a 12-week open-label hetrombopag extension. The primary endpoint was the proportion of patients with a platelet count ≥50 × 10⁹/L at Week 10. The key secondary endpoint was the proportion of patients with a sustained platelet response, defined as a platelet count ≥50 × 10⁹/L maintained for ≥6 weeks without rescue therapy between Weeks 5 and 12. RESULTS: Eighty-eight patients were randomized (hetrombopag, n=57; placebo, n=31). At Week 10, 61.4% of patients in the hetrombopag group achieved the primary endpoint versus 9.7% in the placebo group (absolute difference, 52.7 percentage points; 95% CI, 35.9-69.5; P<0.0001). Sustained response was achieved in 43.9% of hetrombopag-treated patients and 0% of placebo-treated patients (absolute difference, 43.7 percentage points; 95% CI, 28.5-58.9; P<0.0001). Hetrombopag also reduced the need for rescue therapy (21.1% vs 45.2% during double-blind treatment). During the double-blind period, the most common adverse events with hetrombopag were upper respiratory tract infection (57.9% vs 45.2% with placebo) and epistaxis (19.3% vs 22.6%). Alanine aminotransferase elevations occurred in 7.0% of patients on hetrombopag and 0% on placebo. Over 24 weeks, treatment-related hepatotoxicity events (liver enzyme elevations or hepatic function abnormalities) occurred in 17.5% (10/57) of patients receiving continuous hetrombopag; all were grade 1-2 and none led to treatment discontinuation. CONCLUSIONS: Once-daily hetrombopag improved platelet responses, reduced rescue therapy use, and provided durable platelet control with an acceptable safety profile in children and adolescents with ITP. These findings support hetrombopag as an additional oral TPO-RA option for patients with inadequate response or relapse after first-line therapy. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT04737850.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Patient disposition. * Hetrombopag was administered at an initial dose of 2.5 mg. AEs, adverse events
非 KM Figure
Fig. 2Platelet count trends during the 12-week double-blind treatment period. ( A ) Proportion of patients with platelet counts ≥50 × 10⁹/L at each visit; missing data were handled using non-responder imputation (NRI). ( B ) Platelet counts at each scheduled visit; data are presented as mean ± standard error (SE). (C) Cumulative proportion of patients achieving the first documented platelet response (platelet count ≥50 × 10⁹/L) from the first dose of study treatment. CI, confidence interval; NR, not reached; NRI, non-responder imputation; SE, standard error
非 KM Figure
Fig. 3Incidence and severity of bleeding symptoms during the 12-week double-blind, placebo-controlled treatment period. ( A ) Hetrombopag group; ( B) Placebo group. Note: Bleeding severity was graded according to the 2021 Chinese Pediatric ITP Guidelines. Grade 0 (None) indicates no bleeding. Grade 1 (Minor) involves few petechiae (≤100 total) and/or ≤5 small bruises (≤3 cm) without mucosal bleeding. Grade 2 (Mild) includes many petechiae (>100 total) and/or >5 large bruises (>3 cm) without mucosal bleeding. Grade 3 (Moderate) refers to overt mucosal bleeding that interferes with daily life. Grade 4 (Severe) involves mucosal bleeding with a hemoglobin decrease >20 g/L or suspected internal hemorrhage
非 KM Figure